Background and Purpose-Heme and iron are considered to be key factors responsible for secondary insults after intracerebral hemorrhage (ICH). Our previous study showed that LRP1 (low-density lipoprotein receptor-related protein-1)-Hx (hemopexin) facilitates removal of heme. The TLR7 (Toll-like receptor 7)-BTK (Bruton tyrosine kinase)-CRT (calreticulin) pathway regulates the expression of LRP1-Hx. This study is designed to clarify whether TLR7 activation facilitates heme scavenging and to establish the potential role of the BTK-CRT-LRP1-Hx signaling pathway in the pathophysiology of ICH. Methods-ICH was induced by stereotactic, intrastriatal injection of type VII collagenase. Mice received TLR7 agonist (imiquimod) via intraperitoneal injection after ICH induction. TLR7 inhibitor (ODN2088), BTK inhibitor (LFM-A13), and CRT agonist (thapsigargin) were given in different groups to further evaluate the underlying pathway. Mice were randomly divided into sham, ICH+vehicle (normal saline), ICH+Imiquimod (2.5, 5, and 10 μg/g), ICH+ODN2088, ICH+LFM-A13, ICH+thapsigargin, and ICH+ODN2088+thapsigargin. Imiquimod was administered twice daily starting at 6 hours after ICH; ODN2088 was administered by intracerebroventricular injection at 30 minutes, and LFM-A13 or thapsigargin was administered by intraperitoneal injection at 3 hours after ICH induction. Neurological scores, cognitive abilities, as well as brain edema, blood-brain barrier permeability, hemoglobin level, brain expression of TLR7/BTK/ CRT/LRP1/Hx were analyzed.
H emoglobin degradation products, such as heme and iron, are potent cytotoxic molecules that induce oxidative stress, cell death, disruption of the blood-brain barrier (BBB) and are therefore considered key factors responsible for secondary insults after intracerebral hemorrhage (ICH). 1 The human body's primary defense mechanism against heme cytotoxicity is provided by Hx (hemopexin), a serum, and neuronal glycoprotein that binds the heme molecule with high affinity, thereby mitigating its prooxidant effects. 2 The heme-Hx complex is then endocytosed by cells expressing the LRP1 (low-density lipoprotein receptor-related protein-1). 1, 3 Indeed, LRP1 was found to be the main receptor binding heme-Hx, thereby enabling its systemic clearance. 4 The hemeHx-LRP1 complex (LRP1 is also known as CD91) facilitates heme scavenging through microglia/macrophages. 5 Recently, we have demonstrated that activation of the LRP1 system results in neuroprotection after experimental ICH. 1 To further pursue this concept of neuroprotection, we aimed to explore potential pharmacological targets activating LRP1 as a novel therapeutic strategy for ICH.
CRT (calreticulin) is a calcium-binding protein primarily located within the endoplasmic reticulum of phagocytes. Surface-exposed CRT enhances phagocytosis by activating the internalization of LRP1. 6 BTK (Bruton tyrosine kinase) phosphorylates and thereby activates CRT. Accordingly, in the absence of BTK, CRT fails to activate LRP1 internalization at the cell surface, which indicates its importance in regulating phagocytosis via the CRT/LRP1 axis. 7 It has been shown that TLR7 (Toll-like receptor7) stimulation activates BTK, which leads to phosphorylation of CRT and to clearance of hemeHx by the cell-surface receptor LRP1. 7 Therefore, we hypothesize that TLR7 agonism will activate the BTK-CRT-LRP1 pathway resulting in heme-Hx scavenging, thereby facilitating neuroprotection after experimental ICH.
Methods
The original data of this current study can be obtained from the corresponding author on request. All animals were randomized to the control and experimental groups and neurobehavioral testing, as well as quantitative data collection, was conducted in a blinded fashion (animals and sample tubes were marked by numbers, without any identifiers of group allocation).
Animals
All procedures in this study were approved by the Institutional Animal Care and Use Committee at Loma Linda University and comply with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Eight-week-old male CD1 mice (weight 30±5g; Charles River, Wilmington, MA) were housed in a 12-hour light/dark cycle at controlled temperature and humidity with unlimited access to food and water.
ICH Model
The procedure for inducing ICH by stereotactic injection of bacterial collagenase (0.075 U dissolved in 0.5 µL saline, VII-S; Sigma, St Louis, MO) into the basal ganglia were performed as described in our previous publication. 1 Sham-operated mice were subjected to needle insertion only. Vital signs were monitored throughout surgery and recovery period. Neurofunctional testing was performed at preselected time points after ICH induction (6 hours, as well as 1, 3, 7, 14, and 28 days). After neurofunctional testing, animals were euthanized, and brain tissues were collected for measurements of brain water content, hematoma volume, BBB permeability (Evans Blue assay), Western blot, and immunohistochemistry assay as described below.
Experimental Design
Experiments were performed implementing a mouse model of ICH, as shown in Tables I and II in the online-only Data Supplement. Animals were divided into different experimental groups. A total of 231 mice were used. Animals which died before final assessment were replaced. There were no significant differences in the mortality rates between the different experimental groups.
Experiment 1
For our initial outcome evaluation, 177 mice were divided into 5 groups (Table I in the online-only Data Supplement): sham, ICH+vehicle (sterile normal saline), ICH+imiquimod (2.5, 5, and 10 μg/g). The treatment consisted of TLR7 agonist, imiquimod, which was administered twice daily by intraperitoneal injections starting at 6 hours after ICH for 14 days. Neurofunctional testing (modified Garcia test, beam balance, and wire hang tests) and brain edema were evaluated at 24 and 72 hours after ICH; BBB permeability and hemoglobin levels were measured at 24 hours, as well as at 3, 7, and 14 days after ICH. Iron contents were measured at 28 days after ICH. Long-term neurofunctional tests (Morris water maze) were conducted between 23 and 28 days after ICH induction. The vehicle group received the same volume of normal saline.
Experiment 2
For further evaluation of the pharmacological mechanism, 54 mice were used (Table II in the online-only Data Supplement) . We tested the effect of the TLR7 agonist (imiquimod) and its inhibitor (ODN2088). Thirty-three mice were used for the following groups: sham (n=8), ICH+vehicle (n=8), ICH+imiquimod (2.5 μg/g, every 12 hours, intraperitoneally, n=8), ICH+ODN2088 (n=9), ODN2088 (2 μg in 1 μL normal saline, Invivogen, San Diego, CA) was administered by intracerebroventricular injection 30 minutes after the induction of ICH. We then aimed to investigate whether the neuroprotective effects of TLR7 are mediated through BTK-CRT-LRP1-Hx signaling. Twenty-one mice in 3 additional groups were included: ICH+BTK inhibitor (LFM-A13; n=6); ICH+CRT agonist (thapsigargin; n=6 ICH+ODN2088+thapsigargin (n=9). LFM-A13 (25 mg/kg in 1 μL saline, every 12 hours; Sigma, St. Louis, MO) or thapsigargin (2 mg/kg in 1 μL saline; once a day; Sigma) was administered by intraperitoneal injection 3 hours after ICH. The expressions of TLR7/BTK/CRT/LRP1/Hx were evaluated by Western blot analysis. TLR7 expression was also visualized with immunohistochemistry staining.
Intracerebroventricular Injection
As previously described, 1 2 μg ODN2088 was dissolved in 1 μL of sterile normal saline and stereotactically injected into the right lateral ventricle at a rate of 0.25 µL/min (coordinates from Bregma: 0 mm anterior, 1 mm right lateral, and 3.5 mm ventral) using a 26-gauge needle. ODN2088 and its control (1 μL normal saline) was administered 24 hours before induction of ICH.
Neurobehavioral Tests
As previously described, 1 before euthanasia for tissue collection, all animals were subjected to neurofunctional assessments using the modified Garcia, wire hang, and beam balance tests. The modified Garcia test involves a 21-point sensorimotor assessment that includes 7 individual tests. Each test has a score ranging from 0 to 3, with a maximum score of 21. The individual tests evaluate spontaneous activity, response to side stroking, vibrissae touch, limb symmetry, climbing, lateral turning, and forelimb walking. The wire hang and beam balance tests involve either a wire or a beam connecting 2 platforms at either side. Mice were placed on the center of the wire or beam and allowed to reach the platform. The time to reach a platform, as well as the rodent's behavior, was scored. Scores ranged from 0 to 5, with 5 being the best possible test performance.
Morris water maze test was performed to evaluate the effects of the treatment on spatial learning and memory after ICH. This test was conducted in a round pool (100 cm diameter, 60 cm deep) filled with 22°C water rendered opaque with nontoxic white paint. A 10 cm escape platform was submerged 1 cm below the water surface, and the pool was divided into 4 quadrants. Five platform zones (1 in each quadrant and 1 in the center of the pool) were specified in each trial. Mice were tested on days 23 to 28 after ICH. In a conditioning trial, each mouse was released into the pool for 90 seconds, guided to the hidden platform, and allowed to remain there for 15 s. On each of the 4 consecutive testing days, mice were released from one of 4 cardinal drop points. For each trial, mice were placed into the water, facing the edge of the pool, and were allowed to search for the platform for a maximum of 90 s. Mice were placed on the platform for 15 s if they did not find the platform before returning to their heated cages. An overhead camera recorded swim paths. The SMART software (San Diego Instruments, San Diego, CA) analyzed escape latency, swim distances, and linger time in target zones for all trials.
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Measurement of Brain Water Content
The brain water content was measured as previously reported using the wet weight/dry weight method. 1 Brain specimen was weighed on an electronic analytical balance (APX-60, Denver Instrument, Bohemia, NY) to the nearest 0.1 mg to obtain the wet weight. The tissue was then dried at 100°C for 48 hours to determine the dry weight. Brain water content (%) was calculated as ([wet weight−dry weight]/ wet weight)100.
Evans Blue Extravasation
BBB permeability using Evans Blue extravasation was evaluated as previously described.
1 A 2% solution of Evans Blue Dye in normal saline (4 mL/kg of body weight) was injected into the jugular vein. After allowing the dye to circulate for 1 hour, the mice were transcardially perfused with 100 mL of ice-cold PBS. The brain was removed and divided into right and left hemispheres, frozen in liquid nitrogen, and stored at −80°C until analysis. The samples were homogenized in 1100 µL of PBS, sonicated, and centrifuged (30 minutes, 15 000 rcf, 4°C). The supernatant was collected, and for each 500 µL sample, an equal amount of 50% trichloroacetic acid was added. Evans Blue was measured by spectrophotometer (GENESYS 10S UV-Vis spectrophotometer; Thermo Fisher Scientific) at 610 nm and quantified according to a standard curve. The data was calculated as µg of Evans Blue dye/g of tissue and represented as a ratio compared with sham. Values were calculated from spectrophotometer×2/brain weight, then compared with sham values.
Hemoglobin Assay
For hematoma evaluation, supernatant was collected using the same method as for the Evans Blue assay. 1 Drabkin reagent (0.4 mL; SigmaAldrich) was added to 0.1 mL supernatant aliquots and allowed to rest for 15 minutes at room temperature, protected from light. Optical density was measured and recorded at 540 nm with a spectrophotometer (GENESYS 10S UV-Vis spectrophotometer; Thermo Fisher Scientific). These procedures yielded a linear relationship between measured hemoglobin concentrations in perfused brain tissues and the volume of added blood on a standard curve.
Western Blot
Western Blot was performed to measure protein expressions as previously described. 1 Protein samples (50 μg) were loaded on a Tris-glycine gel, electrophoresed, and transferred to a nitrocellulose membrane. Membranes were incubated overnight at 4°C with the primary antibodies: rabbit polyclonal anti-TLR7 (1:5000; Abcam, Cambridge, MA), rabbit monoclonal anti-BTK (1:4000; Cell Signaling, Danvers, MA), rabbit polyclonal anti-CRT (1:5000; Abcam), rabbit polyclonal anti-LRP1 (1:300000, Abcam), and rabbit polyclonal anti-Hx (1:2000; Abcam). The same membrane was probed with an antibody against β-actin (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA) or tubulin (1:5000; Santa Cruz Biotechnology) as an internal control after being stripped. Incubation with secondary antibodies (Santa Cruz Biotechnology) was done for 1 hour at room temperature. Immunoblots were then probed with an enhanced chemiluminescence (ECL Plus reagent kit; Amersham Biosciences, Arlington Heights, IL) and visualized with an imaging system (Versa Doc, Model 4000; Bio-Rad Laboratories, Hercules, CA). Data were analyzed using Image J software.
Immunohistochemistry
Immunohistochemistry was performed as previously described. 8 Whole brains were cut into 10-μm thick coronal sections in a cryostat (CM3050S; Leica Microsystems, Wetzlar, Germany). The sections were incubated overnight at 4°C with the following primary antibodies: rabbit anti-TLR7 (1:100; Abcam), goat anti-Iba1 (ionized calcium-binding adaptor molecule 1, 1:100; Abcam), goat anti-GFAP (glial fibrillary acidic protein, 1:100; Santa Cruz), mouse anti RECA-1 (rat endothelial cell antibody 1, 1:100; Abcam), and rabbit anti-NeuN (neuronal nuclei, 1:100; Abcam) followed by incubation with appropriate fluorescein isothiocyanate-conjugated or Alexa Fluor-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Negative control staining was performed by omitting the primary antibody. Perihemorrhagic areas of the brain coronal sections were visualized with a fluorescence microscope (BX51; Olympus Corporation, Tokyo, Japan).
Iron Staining and Iron Content
Iron staining and iron content were evaluated as previously described. 9 Brain sections were stained with Perls Prussian blue to identify ferric ion (Fe 3+ 
Statistical Analysis
Quantitative data are presented as mean±SD. One-way ANOVA for multiple comparisons with Tukey post hoc test was used to determine the differences of brain water contents and Western blot assay among all groups at each time point. Two-way ANOVA with Bonferroni post-test was used to assay the differences of neurological deficits. P<0.05 was considered statistically significant.
Results

Mortality
All sham-operated mice survived. The total operative mortality of mice subjected to ICH was 8.2 % (n=19). The mortality was not significantly different among the experimental groups (data not shown).
TLR7 Agonist, Imiquimod, Decreased Hematoma Volume and Ameliorated BBB Disruption and Brain Edema
All ICH groups showed a significant increase in brain water content, hemoglobin levels, and Evans blue extravasation when compared with sham at 24 hours after surgery (P<0.05, Figure 1A , 1C, and 1D). Imiquimod 5 and 10 μg/g treatment resulted in lower hemoglobin levels at 24 hours after collagenase injection when compared to the vehicle group; however, there were no significant differences between imiquimod 2.5 μg/g treatment and the vehicle group. Imiquimod 2.5 and 5 μg/g treatment reduced hemoglobin levels (hematoma volumes) at 72 hours after collagenase injection compared with the vehicle group ( Figure 1D ), but only 2.5 μg/g imiquimod reduced brain water content and BBB permeability at 24 and 72 hours after ICH when compared with the ICH+vehicle group (P<0.05, Figure 1A-1C) .
Low-Dose Imiquimod Improved Short-Term Neurological Deficits After ICH
ICH+vehicle animals scored significantly lower compared with sham mice in all neurofunctional tests performed at Considering these results, we chose 2.5 μg/g imiquimod to examine the long-term neurofunctional tests and the pharmacological mechanisms of TLR7 at 72 hours after ICH for further studies.
Imiquimod Improved Long-Term Neurofunctional Deficits After ICH
Results of the Morris Water Maze showed that low dose imiquimod improved the spatial memory after ICH (P<0.05, Figure 2A-2D) . Figure 2A is a visualization of the swimming track and heat map; ( Figure 2B ) demonstrates the mean latency to escape onto the platform; ( Figure 2C ) demonstrates the mean swimming distances before escaping onto the platform; and ( Figure 2D ) shows the mean platform searching times within the target quadrant during the probe trial on the sixth day of testing. Specifically, imiquimod-treated ICH mice showed shorter routes traveled compared with vehicle animals.
During the first day of testing (with the platform being visible above the water surface), sham, imiquimod-treated, and vehicle mice exhibited a similar latency to reach the platform. In subsequent testing (with the platform being hidden below the water surface), imiquimod-treated ICH mice showed a shorter latency to escape onto the platform on the third and fourth day of the Water Maze experiments. Compared with vehicle animals, imiquimod-treated mice demonstrated a shorter swimming length before escaping onto the hidden platform on the second and fourth day of testing. In the probe trial on the sixth day of testing, imiquimod-treated mice traveled significantly more within the target quadrant (where the rescue platform used to be) than vehicle animals.
Imiquimod Reduced Iron Levels After ICH
Iron staining and iron contents were measured on day 28 after ICH induction, on completion of Morris Water Maze testing. Imiquimod-treated ICH mice exhibited decreased iron contents in the ipsilateral brain hemispheres as compared to vehicle group (P<0.05; Figure 3 ).
TLR7 Treatment Was Mediated Through BTK-CRT-LRP1-Hx Signaling
Western blot analysis was implemented to measure the protein expression of TLR7, BTK, CRT, LRP1, and Hx within the ipsilateral brain hemisphere. TLR7, BTK, CRT, LRP1, 
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Double immunofluorescence staining was completed in the perihematomal brain tissue (Figure 6 ). Fluorescent staining demonstrated that TLR7 was expressed in microglia (Iba1; Figure 6A ), astrocytes (GFAP; Figure 6B ), endothelial cells of brain vessels (RECA; Figure 6C ), and neurons (NeuN; Figure 6D ). Additionally, fluorescence of TLR7 revealed increased expression in vehicle and imiquimod-treated groups while showing a decreased expression Figure 6 . Representative immunohistochemistry microphotographs of TLR7 (Toll-like receptor 7) with Iba1 (ionized calcium-binding adaptor molecule 1; A), TLR7 and GFAP (glial fibrillary acidic protein; B), TLR7 and RECA (rat endothelial cell antibody; C) (Continued ) in animals that received ODN2088 and ODN2088 combined with thapsigargin, thus supporting the Western blot results.
Discussion
In the present study, we have made the following observations: (1) The TLR7 agonist, imiquimod significantly attenuated hematoma volume, ICH-induced brain edema, BBB permeability, and neurofunctional deficits at 24 hours and 3 days after ICH. (2) Imiquimod also improved spatial memory and reduced iron levels in mice 28 days after ICH. (3) Endogenous TLR7, BTK, CRT, LRP1, and Hx levels were significantly elevated in the ipsilateral brain hemispheres at 3 days after ICH induction. (4) Imiquimod treatment resulted in increased protein expressions of TLR7, BTK, CRT, LRP1, and Hx, whereas the TLR7 inhibitor, ODN2088, resulted in Our group has recently reported that LRP1 contributes to heme clearance and subsequent BBB protection after ICH by reinforcing the effect of Hx. The signaling pathway through LRP1 seems to be modulating heme scavenging after ICH. 1 Hx is a plasma glycoprotein able to bind heme with a high affinity, 5, 10 which clears heme in a nontoxic form and transports it to the liver for catabolism and evacuation. 11 The specific mechanism of Hx in ICH will be explored in future studies. In this current study, we observed imiquimod increased Hx levels after ICH. It might be possible that heme-Hx uptake via LRP1 was saturated after ICH. Since LRP1 might have been completely occupied, its endocytosis and therefore heme degradation was reduced. Imiquimod-enhanced LRP1 expression at the BBB indirectly increased Hx levels and stimulate heme efflux from the brain. Therefore, activating LRP1 could be a therapeutic strategy to scavenge toxic hematoma products after ICH.
Erythrophagocytosis can be mediated by the interaction between CRT on the target cell and LRP1 (CD91/α2-macroglobulin receptor) on the macrophage. 12 CRT and LRP1 functions at the cell membrane and regulate uptake of apoptotic cells or debris. BTK is critical in regulating CRTdriven apoptotic cell uptake, as it directly phosphorylates CRT and without BTK, CRT fails to localize with LRP1 at the cell surface and at the phagocytic cup. 7 BTK plays a key role in macrophage stimulation by various TLRs. 13 TLRs are a class of pattern recognition receptors that play a bridging role in innate immunity and adaptive immunity.
14 The stimulation of TLRs leads to the initiation of intracellular signal transduction pathways regulating macrophagic activation and effector functions. 15 TLR7, a member of TLR family, is an intracellular receptor expressed on the membrane of endosomes.
14 TLR7 stimulation results in activation of BTK, which plays an important role in facilitating the tyrosine phosphorylation of CRT. Rectification of CRT via BTK is important for control of the trafficking of CRT within myeloid cells. Trafficking of CRT to the cell surface facilitates colocalization with the cell-surface receptor LRP1. 7 Therefore, stimulation of TLR7 could activate phagocytosis through the BTK-CRT-LRP1 pathway. Consistent with this hypothesis, our study utilized TLR7 inhibitor, ODN2088 administration, which suppressed TLR7-BTK-CRT-LRP1-Hx expression in the brain. It further reversed the role of TLR7 agonist on the BTK-CRT-LRP1-Hx pathway. The BTK inhibitor also suppressed CRT-LRP1-Hx expression, confirming the role of TLR7 in ICH is likely mediated via the BTK-CRT-LRP1-Hx pathway.
Microglia and astrocytes are the major immune cells of the brain and express a full repertoire of TLR7. 16, 17 TLR7 is expressed in brain capillary endothelial cells, 18 as well as in peripheral neurons. 19 Our results verified that TLR7 is mainly expressed on the dendrites of astroglia, endothelial cells, and microglia, especially in the choroid plexus. TLR7-dependent astrocyte activation could be mediated by cytokines and chemokines that are produced after TLR7 stimulation in macrophages or microglia. 17 Alternatively, TLR7-dependent activation of phagocytes may be direct after endocytosis of the foreign microbes, necrotic cells, and debris. The main target cells of TLR7 agonists are dendritic cells, producing IFN (interferon)-γ then acting on other immune cells.
20 TLR7 agonist, imiquimod, is an immunomodulatory, synthetic smallmolecule compound of the imidazoquinoline family that displays both antiviral and antitumor effects. [21] [22] [23] [24] [25] Imiquimod has been shown to activate a variety of genes associated with macrophage activation. 26, 27 Thus, imiquimod could induce leukocyte infiltration and inflammation, thereby aggravating brain swelling. 24 This could explain why the low dose but not the high dose of imiquimod was found to be effective in our study after experimental ICH in mice. The phagocytosis of imiquimod in ICH could be explained by its induced substantial astrocyte responses in vivo.
28 TLR7-dependent activation of phagocytes might explain the early neuroprotective effects of imiquimod on the first day after ICH, which indicate that the therapeutic benefits of imiquimod may have other actions than heme-Hx scavenging-dependent mechanisms because hemoglobin/heme releasing from red blood cells after ICH starts occurs mostly after 24 hours after ICH. Our immunohistochemical staining demonstrated that imiquimod enhanced the expression of TLR7 on astrocytes after ICH. Furthermore, our study used intraperitoneal imiquimod administration and found activated TLR7 expression in the brain, which further reduced heme levels and thereby attenuated brain edema, BBB permeability and heme metabolites-iron deposits around the hematoma, confirming the protective role of TLR7 after ICH.
In conclusion, our study highlights the role of TLR7, evaluated by administration of TLR7 agonist, imiquimod, and TLR7 inhibitor, ODN2088, in the setting of experimental murine ICH. Imiquimod facilitates heme scavenging and exerts neuroprotective effects after ICH via activation of the BTK-CRT-LRP1-Hx pathway. Selective TLR7 inhibition partially reversed the effects associated with TLR7 agonist. Thus, TLR7 may offer protective effects through promoting heme and iron scavenging and thereby diminishing brain edema after ICH, which may prove beneficial in post-ICH outcomes. The efficacy and clinical limitations of TLR7 should be addressed in the future studies.
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